NASDAQ:RYTM Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis $49.05 -0.56 (-1.13%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$49.05▼$50.7450-Day Range$35.41▼$53.8952-Week Range$17.34▼$53.92Volume295,204 shsAverage Volume594,359 shsMarket Capitalization$2.99 billionP/E RatioN/ADividend YieldN/APrice Target$55.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Rhythm Pharmaceuticals alerts: Email Address Rhythm Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside13.8% Upside$55.83 Price TargetShort InterestBearish16.52% of Shares Sold ShortDividend StrengthN/ASustainability-1.80Upright™ Environmental ScoreNews Sentiment0.57Based on 13 Articles This WeekInsider TradingSelling Shares$973,772 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.45) to ($2.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.39 out of 5 starsMedical Sector550th out of 936 stocksPharmaceutical Preparations Industry249th out of 436 stocks 2.4 Analyst's Opinion Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRhythm Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Rhythm Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.52% of the outstanding shares of Rhythm Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 18.3, which indicates bearish sentiment.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently increased by 8.98%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRhythm Pharmaceuticals does not currently pay a dividend.Dividend GrowthRhythm Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRhythm Pharmaceuticals has received a 63.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Anti-obesity medication (A08)", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Rhythm Pharmaceuticals is -1.80. Previous Next 2.0 News and Social Media Coverage News SentimentRhythm Pharmaceuticals has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Rhythm Pharmaceuticals this week, compared to 6 articles on an average week.MarketBeat FollowsOnly 1 people have added Rhythm Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $973,772.00 in company stock.Percentage Held by InsidersOnly 5.60% of the stock of Rhythm Pharmaceuticals is held by insiders.Read more about Rhythm Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($4.45) to ($2.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rhythm Pharmaceuticals is -10.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rhythm Pharmaceuticals is -10.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRhythm Pharmaceuticals has a P/B Ratio of 17.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Rhythm Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM)Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Read More RYTM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RYTM Stock News HeadlinesJuly 19, 2024 | insidertrades.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells $554,804.00 in StockJuly 17, 2024 | insidertrades.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells 5,313 Shares of StockJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.July 25 at 5:02 PM | bizjournals.comMeet Rhythm Healthcare, a 2024 Fast 50 honoreeJuly 25 at 5:02 PM | markets.businessinsider.comBuy Rating Affirmed for Rhythm Pharmaceuticals on Strong Drug Pipeline and Market PotentialJuly 25 at 8:28 AM | americanbankingnews.comRhythm Pharmaceuticals (NASDAQ:RYTM) Given New $55.00 Price Target at Needham & Company LLCJuly 23 at 4:44 PM | msn.comLimited camping tickets remaining for Colne's much loved Rhythm & Blues festivalJuly 23 at 4:44 PM | msn.comGunning for Glory: Rhythm looks to carve out her own identity in ParisJuly 26, 2024 | Crypto 101 Media (Ad)Brace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.July 23 at 4:44 PM | msn.comRhythm Loses a Beat on Test ResultsJuly 23 at 4:44 PM | markets.businessinsider.comRhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic ObesityJuly 23 at 7:30 AM | globenewswire.comRhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024July 22, 2024 | americanbankingnews.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJuly 20, 2024 | americanbankingnews.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Joseph Shulman Sells 10,468 SharesJuly 17, 2024 | americanbankingnews.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Joseph Shulman Sells 5,313 SharesJuly 16, 2024 | americanbankingnews.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Short Interest Down 16.3% in JuneJuly 11, 2024 | globenewswire.comRhythm Pharmaceuticals Announces New Employment Inducement GrantsJune 28, 2024 | globenewswire.comRhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR DeficiencySee More Headlines Receive RYTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Confirmed)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RYTM CUSIPN/A CIK1649904 Webwww.rhythmtx.com Phone(857) 264-4280Fax857-264-4299Employees140Year FoundedN/APrice Target and Rating Average Stock Price Target$55.83 High Stock Price Target$79.00 Low Stock Price Target$42.00 Potential Upside/Downside+13.8%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($4.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-184,680,000.00 Net Margins-297.91% Pretax Margin-296.99% Return on Equity-179.26% Return on Assets-87.25% Debt Debt-to-Equity RatioN/A Current Ratio4.35 Quick Ratio4.20 Sales & Book Value Annual Sales$77.43 million Price / Sales38.62 Cash FlowN/A Price / Cash FlowN/A Book Value$2.87 per share Price / Book17.09Miscellaneous Outstanding Shares60,970,000Free Float57,559,000Market Cap$2.99 billion OptionableOptionable Beta2.04 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. David P. Meeker M.D. (Age 70)Chairman, President & CEO Comp: $1.35MMr. Hunter C. Smith M.B.A. (Age 55)CFO & Treasurer Comp: $757.32kMr. Joseph Shulman (Age 48)Chief Technical Officer Comp: $677.27kMr. Yann Mazabraud (Age 51)Executive VP & Head of International Comp: $936.91kMs. Jennifer Lee (Age 48)Executive VP & Head of North America Comp: $727.14kMr. Christopher German (Age 53)Corporate Controller, Principal Accounting Officer & Executive Director Mr. David ConnollyHead of Investor Relations & Corporate CommunicationsMr. Jim FlahertySenior VP & General CounselMs. Sarah RyanVice President of Sales & MarketingMs. Pamela J. Cramer (Age 49)Chief Human Resources Officer More ExecutivesKey CompetitorsPliant TherapeuticsNASDAQ:PLRXAnnexonNASDAQ:ANNXTheravance BiopharmaNASDAQ:TBPHCatalentNYSE:CTLTQiagenNYSE:QGENView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 24,033 shares on 7/26/2024Ownership: 0.315%Nisa Investment Advisors LLCBought 229,056 shares on 7/20/2024Ownership: 0.614%Hennion & Walsh Asset Management Inc.Bought 9,411 shares on 7/20/2024Ownership: 0.158%Assenagon Asset Management S.A.Sold 56,160 shares on 7/18/2024Ownership: 0.376%Wedge Capital Management L L P NCSold 10,676 shares on 7/17/2024Ownership: 0.104%View All Insider TransactionsView All Institutional Transactions RYTM Stock Analysis - Frequently Asked Questions How have RYTM shares performed this year? Rhythm Pharmaceuticals' stock was trading at $45.97 at the beginning of 2024. Since then, RYTM shares have increased by 6.7% and is now trading at $49.05. View the best growth stocks for 2024 here. How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) announced its quarterly earnings results on Tuesday, May, 7th. The company reported ($2.35) EPS for the quarter, missing analysts' consensus estimates of ($2.34) by $0.01. The company's revenue for the quarter was up 126.1% on a year-over-year basis. When did Rhythm Pharmaceuticals IPO? Rhythm Pharmaceuticals (RYTM) raised $100 million in an IPO on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager. Who are Rhythm Pharmaceuticals' major shareholders? Rhythm Pharmaceuticals' top institutional shareholders include Nisa Investment Advisors LLC (0.61%), Assenagon Asset Management S.A. (0.38%), Bank of New York Mellon Corp (0.31%) and Hennion & Walsh Asset Management Inc. (0.16%). Insiders that own company stock include David P Meeker, Hunter C Smith, Yann Mazabraud, Pamela J Cramer, William T Roberts, Jennifer Chien, Jennifer Kayden Lee, Christopher Paul German and Joseph Shulman. View institutional ownership trends. How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Rhythm Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN) and Kadmon (KDMN). This page (NASDAQ:RYTM) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RYTM Stock Alerts